First Time Loading...

Arvinas Inc
NASDAQ:ARVN

Watchlist Manager
Arvinas Inc Logo
Arvinas Inc
NASDAQ:ARVN
Watchlist
Price: 32.54 USD -4.29% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

ARVN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. [ Read More ]

The intrinsic value of one ARVN stock under the Base Case scenario is 11.8 USD. Compared to the current market price of 32.54 USD, Arvinas Inc is Overvalued by 64%.

Key Points:
ARVN Intrinsic Value
Base Case
11.8 USD
Overvaluation 64%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arvinas Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ARVN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Arvinas Inc

Provide an overview of the primary business activities
of Arvinas Inc.

What unique competitive advantages
does Arvinas Inc hold over its rivals?

What risks and challenges
does Arvinas Inc face in the near future?

Has there been any significant insider trading activity
in Arvinas Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Arvinas Inc.

Provide P/S
for Arvinas Inc.

Provide P/E
for Arvinas Inc.

Provide P/OCF
for Arvinas Inc.

Provide P/FCFE
for Arvinas Inc.

Provide P/B
for Arvinas Inc.

Provide EV/S
for Arvinas Inc.

Provide EV/GP
for Arvinas Inc.

Provide EV/EBITDA
for Arvinas Inc.

Provide EV/EBIT
for Arvinas Inc.

Provide EV/OCF
for Arvinas Inc.

Provide EV/FCFF
for Arvinas Inc.

Provide EV/IC
for Arvinas Inc.

Show me price targets
for Arvinas Inc made by professional analysts.

What are the Revenue projections
for Arvinas Inc?

How accurate were the past Revenue estimates
for Arvinas Inc?

What are the Net Income projections
for Arvinas Inc?

How accurate were the past Net Income estimates
for Arvinas Inc?

What are the EPS projections
for Arvinas Inc?

How accurate were the past EPS estimates
for Arvinas Inc?

What are the EBIT projections
for Arvinas Inc?

How accurate were the past EBIT estimates
for Arvinas Inc?

Compare the revenue forecasts
for Arvinas Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Arvinas Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Arvinas Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Arvinas Inc compared to its peers.

Compare the P/E ratios
of Arvinas Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Arvinas Inc with its peers.

Analyze the financial leverage
of Arvinas Inc compared to its main competitors.

Show all profitability ratios
for Arvinas Inc.

Provide ROE
for Arvinas Inc.

Provide ROA
for Arvinas Inc.

Provide ROIC
for Arvinas Inc.

Provide ROCE
for Arvinas Inc.

Provide Gross Margin
for Arvinas Inc.

Provide Operating Margin
for Arvinas Inc.

Provide Net Margin
for Arvinas Inc.

Provide FCF Margin
for Arvinas Inc.

Show all solvency ratios
for Arvinas Inc.

Provide D/E Ratio
for Arvinas Inc.

Provide D/A Ratio
for Arvinas Inc.

Provide Interest Coverage Ratio
for Arvinas Inc.

Provide Altman Z-Score Ratio
for Arvinas Inc.

Provide Quick Ratio
for Arvinas Inc.

Provide Current Ratio
for Arvinas Inc.

Provide Cash Ratio
for Arvinas Inc.

What is the historical Revenue growth
over the last 5 years for Arvinas Inc?

What is the historical Net Income growth
over the last 5 years for Arvinas Inc?

What is the current Free Cash Flow
of Arvinas Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Arvinas Inc.

Financials

Balance Sheet Decomposition
Arvinas Inc

Current Assets 1.3B
Cash & Short-Term Investments 1.3B
Receivables 7.2m
Other Current Assets 12m
Non-Current Assets 24.4m
PP&E 14m
Other Non-Current Assets 10.4m
Current Liabilities 257.1m
Accounts Payable 110m
Accrued Liabilities 75.6m
Other Current Liabilities 71.5m
Non-Current Liabilities 387.5m
Long-Term Debt 800k
Other Non-Current Liabilities 386.7m
Efficiency

Earnings Waterfall
Arvinas Inc

Revenue
78.5m USD
Operating Expenses
-480m USD
Operating Income
-401.5m USD
Other Expenses
34.2m USD
Net Income
-367.3m USD

Free Cash Flow Analysis
Arvinas Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

ARVN Profitability Score
Profitability Due Diligence

Arvinas Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Negative Free Cash Flow
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
55/100
Profitability
Score

Arvinas Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

ARVN Solvency Score
Solvency Due Diligence

Arvinas Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
63/100
Solvency
Score

Arvinas Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARVN Price Targets Summary
Arvinas Inc

Wall Street analysts forecast ARVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARVN is 72.25 USD with a low forecast of 49.49 USD and a high forecast of 115.5 USD.

Lowest
Price Target
49.49 USD
52% Upside
Average
Price Target
72.25 USD
122% Upside
Highest
Price Target
115.5 USD
255% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ARVN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ARVN Price
Arvinas Inc

1M 1M
-20%
6M 6M
+126%
1Y 1Y
+20%
3Y 3Y
-51%
5Y 5Y
+44%
10Y 10Y
+103%
Annual Price Range
32.54
52w Low
14.19
52w High
52.31
Price Metrics
Average Annual Return 30.87%
Standard Deviation of Annual Returns 75.37%
Max Drawdown -87%
Shares Statistics
Market Capitalization 2.2B USD
Shares Outstanding 68 083 904
Percentage of Shares Shorted 14.09%

ARVN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Arvinas Inc Logo
Arvinas Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

2.2B USD

Dividend Yield

0%

Description

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 280 full-time employees. The company went IPO on 2018-09-27. The firm is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three lead product candidates are ARV-110, ARV-471 and ARV-766. The company develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). The company develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The company develops ARV-766, a PROTAC protein degrader for the treatment of men with metastatic castration-resistant prostate.

Contact

CONNECTICUT
New Haven
5 Science Park
+12035351456.0
http://arvinas.com/

IPO

2018-09-27

Employees

280

Officers

Chairperson, CEO & President
Dr. John G. Houston Ph.D.
Chief Scientific Officer
Dr. Ian Taylor Ph.D.
Interim CFO & Treasurer
Dr. Randy Teel Ph.D.
VP, Principal Accounting Officer & Chief Accounting Officer
Mr. David K. Loomis M.B.A.
Vice President of Investor Relations
Mr. Jeff Boyle
General Counsel & Corporate Secretary
Mr. Jared M. Freedberg J.D.
Show More
Senior VP & Chief Human Resources Officer
Mr. Steve Weiss
Senior Vice President of R&D Technical Operations
Dr. John A. Grosso Ph.D.
Senior Vice President of Neuroscience & Platform Biology
Ms. Angela M. Cacace Ph.D.
Chief Commercial Officer
Mr. John P. Northcott
Show Less

See Also

Discover More
What is the Intrinsic Value of one ARVN stock?

The intrinsic value of one ARVN stock under the Base Case scenario is 11.8 USD.

Is ARVN stock undervalued or overvalued?

Compared to the current market price of 32.54 USD, Arvinas Inc is Overvalued by 64%.